Form 4: Fortress Biotech Director Kevin Lorenz Acquires and Disposes of Shares

Director Kevin Lorenz receives restricted stock grant and disposes of shares in Fortress Biotech, Inc.

Summary

• On January 1, 2025, Kevin Lorenz, a director of Fortress Biotech, Inc., acquired 49,383 shares of restricted stock.
• These shares were granted under the Issuer's 2013 Stock Incentive Plan, as amended.
• One-third of the shares will vest annually on January 1, 2026, 2027, and 2028, contingent upon continued service.
• Lorenz also disposed of 73,687 shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing stock transactions by a company director. The sentiment is neutral as it simply reports facts without expressing any positive or negative outlook.

Positives

• The grant of restricted stock to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's long-term success.

Risks

• The vesting of the restricted stock is contingent upon continued service, meaning that if the director leaves the company before the vesting dates, they will forfeit the unvested shares.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the restricted stock indicates a multi-year commitment from the director.

Industry Context

Stock grants to directors are a common practice in the biotech industry to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen often use stock options and restricted stock units to incentivize their executives.
• The vesting schedules, typically ranging from three to five years, are designed to retain key personnel and align their interests with long-term shareholder value.

Stakeholder Impact

• The stock grant could have a slightly positive impact on shareholders as it incentivizes the director to work towards increasing shareholder value.
• The vesting schedule ensures the director's continued commitment to the company.

Key Dates